AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31359765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity jogging (15 minutes)
Number of subjects: 112
Study 30852960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine, 1:100,000 of adrenaline and 8.4% sodium bicarbonate; given 30 min prior to procedure
Number of subjects: 86
Study 30852960 — intervention group
Group type: COMPARATOR
Intervention: 1% lignocaine and 8.4% sodium bicarbonate with arm tourniquet; given 10 min prior to procedure
Number of subjects: 86
Study 28370210 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment (three-monthly single-dose)
Number of subjects: 1494
Study 28370210 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 1494
Study 25675113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized Japanese cedar pollen extract for 5 months
Number of subjects: 15
Study 25675113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive placebo) for 5 months
Number of subjects: 15
Study 25675113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 15
Study 25675113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive placebo)
Number of subjects: 15
Study 23616512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake with SFAs (54% of energy/total fat)
Number of subjects: 36
Study 23616512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake with MUFAs (83% of energy/total fat)
Number of subjects: 36
Study 23616512 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake with n3 PUFAs (40% of energy/total fat)
Number of subjects: 36
Study 23616512 — intervention group
Group type: EXPERIMENTAL
Intervention: All high-fat milkshakes
Number of subjects: 36
Study 21749236 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation intervention
Number of subjects: 0
Study 19001792 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched fat blend (0.69 g/day)
Number of subjects: 23
Study 19001792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17283875 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (hydroxyethyl starch 130/0.4, 60 g/L)
Number of subjects: 66
Study 17283875 — intervention group
Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 66
Study 15544251 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld computer (iPAQ 3670 running Pocket PC)
Number of subjects: 23
Study 15544251 — intervention group
Group type: COMPARATOR
Intervention: CRT monitor
Number of subjects: 23
Study 15544251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (crossover design)
Number of subjects: 23
Study 11314681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1.5 mg
Number of subjects: 18
Study 11314681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg
Number of subjects: 18
Study 11314681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9444567 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired stimulation of the supraorbital nerve
Number of subjects: 23
Study 9444567 — intervention group
Group type: EXPERIMENTAL
Intervention: Index finger stimulation
Number of subjects: 23
Study 9444567 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 23
Study 7898994 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonic group
Number of subjects: 24
Study 7898994 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 3107495 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg)
Number of subjects: 24
Study 3107495 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (480 mg)
Number of subjects: 24
Study 3107495 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study 31166426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation glaucoma
Number of subjects: 90
Study 31166426 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open angle glaucoma
Number of subjects: 90
Study 31166426 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 90
Study 28332096 — intervention group
Group type: COMPARATOR
Intervention: Paricalcitol (3 μg)
Number of subjects: 49
Study 28332096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28332096 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (no comparator)
Number of subjects: 49
Study 26133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Program (SMP) consisting of relaxation-breathing and guided imagery before and 8 weeks after CEA
Number of subjects: 24
Study 26133996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stress management intervention)
Number of subjects: 24
Study 26133996 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Program (SMP)
Number of subjects: 24
Study 23286829 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvented jet nebulizer with corrugated tubing (N2)
Number of subjects: 7
Study 23286829 — intervention group
Group type: COMPARATOR
Intervention: Open-vent jet nebulizer (N1)
Number of subjects: 7
Study 21615955 — intervention group
Group type: EXPERIMENTAL
Intervention: $5 monetary incentive
Number of subjects: 1328
Study 21615955 — intervention group
Group type: COMPARATOR
Intervention: $2 monetary incentive
Number of subjects: 1328
Study 18165577 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with ropivacaine (1.5 mg/kg, max 150 mg)
Number of subjects: 50
Study 18165577 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with ropivacaine
Number of subjects: 50
Study 18165577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) TAP block
Number of subjects: 50
Study 16096330 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 200
Study 16096330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical prostatectomy performed by senior surgeons
Number of subjects: 100
Study 12893342 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical prostatectomy performed by junior surgeons
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical prostatectomy with lymph node dissection
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical prostatectomy with sural nerve grafting
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical prostatectomy only by senior surgeons
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical prostatectomy with lymph node dissection and sural nerve grafting by junior surgeons
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 obesity
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a surgical robot
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon experience
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate weight
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior abdominal surgery
Number of subjects: 100
Study 12893342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve sparing
Number of subjects: 100
Study 10786733 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml of 4% nebulized lignocaine
Number of subjects: 48
Study 10786733 — intervention group
Group type: COMPARATOR
Intervention: Combined regional block (CRB) including translaryngeal block, bilateral superior laryngeal nerve block, and three 4% lignocaine-soaked cotton swabs in the nose
Number of subjects: 48
Study 9310813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (7.5 MHz)
Number of subjects: 79
Study 9310813 — intervention group
Group type: COMPARATOR
Intervention: Control group (anatomical landmarks)
Number of subjects: 79
Study 9310813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 79
Study 8368636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (1,436 subjects) - 1.75 mg of formaldehyde‐killed spherules of Coccidioides immitis, administered as three intramuscular injections
Number of subjects: 2867
Study 8368636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1,431 subjects) - sterile 0.85% NaCl solution, administered as three injections
Number of subjects: 2867
Study 3716812 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg after 1 night of medication
Number of subjects: 18
Study 3716812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg after 1 night of medication
Number of subjects: 18
Study 3716812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg after 3 nights of medication
Number of subjects: 18
Study 3716812 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 1 night of medication
Number of subjects: 18
Study 3716812 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 3 nights of medication
Number of subjects: 18
Study 3716812 — intervention group
Group type: EXPERIMENTAL
Intervention: Real car driving with Nitrazepam
Number of subjects: 18
Study 3716812 — intervention group
Group type: EXPERIMENTAL
Intervention: Real car driving with Triazolam
Number of subjects: 18
Study 3716812 — intervention group
Group type: COMPARATOR
Intervention: Real car driving with Placebo
Number of subjects: 18
Study 29269509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa Model for Smoking Cessation (OMSC) intervention
Number of subjects: 313
Study 29269509 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 313
Study 26959612 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-pelvic (WP) volumetric-modulated arc therapy (VMAT) at 46.8 Gy in 26 fractions
Number of subjects: 224
Study 26959612 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only (PO) volumetric-modulated arc therapy (VMAT)
Number of subjects: 224
Study 24384429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-length adult-colonoscope
Number of subjects: 239
Study 24384429 — intervention group
Group type: COMPARATOR
Intervention: Long-length adult-colonoscope
Number of subjects: 239
Study 22033811 — intervention group
Group type: EXPERIMENTAL
Intervention: Early part-time sick leave
Number of subjects: 63
Study 22033811 — intervention group
Group type: COMPARATOR
Intervention: Full-time sick leave
Number of subjects: 63
Study 20093512 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 25
Study 20093512 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 2.5 mg
Number of subjects: 25
Study 18277518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperators
Number of subjects: 0
Study 18277518 — intervention group
Group type: EXPERIMENTAL
Intervention: Defectors
Number of subjects: 0
Study 18277518 — intervention group
Group type: EXPERIMENTAL
Intervention: Players who cooperated
Number of subjects: 0
Study 18277518 — intervention group
Group type: EXPERIMENTAL
Intervention: Players projecting their own attitudes onto others
Number of subjects: 0
Study 15604051 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stages of change in exercise
Number of subjects: 1234
Study 15604051 — intervention group
Group type: COMPARATOR
Intervention: Older age groups
Number of subjects: 1234
Study 12088808 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative IV morphine
Number of subjects: 200
Study 12088808 — intervention group
Group type: COMPARATOR
Intervention: Postoperative IV meperidine
Number of subjects: 200
Study 9484821 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 160 mg t.i.d. for 8 days before each chemotherapy cycle
Number of subjects: 130
Study 9484821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 8587269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.55 g/kg/day)
Number of subjects: 14
Study 8587269 — intervention group
Group type: COMPARATOR
Intervention: High-protein diet (2 g/kg/day)
Number of subjects: 14
Study 8587269 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (comparable reductions in blood pressure)
Number of subjects: 14
Study 2663900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin 0.15 mg/kg BID
Number of subjects: 0
Study 2663900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin 0.35 mg/kg BID
Number of subjects: 0
Study 2663900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin (both doses)
Number of subjects: 0
Study 786807 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 150
Study 786807 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamide
Number of subjects: 150
Study 786807 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic cover)
Number of subjects: 150
Study 31216065 — intervention group
Group type: EXPERIMENTAL
Intervention: RecoverMI (experimental arm)
Number of subjects: 30
Study 31216065 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (control arm)
Number of subjects: 30
Study 27806919 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Stent (DCS)
Number of subjects: 2466
Study 27806919 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stent (BMS)
Number of subjects: 2466
Study 27898256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser (LLL) therapy (780 nm laser, dose of 35.0 J/cm2, for 20 sec, thrice a week, for 4 weeks)
Number of subjects: 60
Study 27898256 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic and Drug Protocol (PDP) (hot packs thrice a day for 15 min, mouth exercises twice a day, myorelaxing and anti-inflammatory drugs)
Number of subjects: 60
Study 27898256 — intervention group
Group type: COMPARATOR
Intervention: Placebo (450 nm halogen lamp)
Number of subjects: 60
Study 24037972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants who were 'imitators' during the task
Number of subjects: 0
Study 24037972 — intervention group
Group type: COMPARATOR
Intervention: Adults
Number of subjects: 0
Study 24037972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants (general observation)
Number of subjects: 0
Study 22448235 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for 18 months
Number of subjects: 89
Study 22448235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 20135944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannequin simulator
Number of subjects: 30
Study 20135944 — intervention group
Group type: COMPARATOR
Intervention: Porcine model (non-simulator)
Number of subjects: 30
Study 18025896 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 16102863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone signal (902.40 MHz, modulated at 217 Hz, with an average power of 0.25 W) during EEG recording session
Number of subjects: 20
Study 16102863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone signal (902.40 MHz, modulated at 217 Hz, with an average power of 0.25 W) before EEG recording session
Number of subjects: 20
Study 16102863 — intervention group
Group type: COMPARATOR
Intervention: Baseline and sham conditions
Number of subjects: 20
Study 12160274 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone appointment visits
Number of subjects: 153
Study 12160274 — intervention group
Group type: COMPARATOR
Intervention: Physician office visits
Number of subjects: 153
Study 10594418 — intervention group
Group type: COMPARATOR
Intervention: Conventional bevel tracheal tube
Number of subjects: 70
Study 10594418 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bevel tracheal tube
Number of subjects: 70
Study 8536300 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine administration
Number of subjects: 0
Study 8536300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1517428 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐reinforced poly‐L‐lactide (SR‐PLLA) screw
Number of subjects: 7
Study 1517428 — intervention group
Group type: COMPARATOR
Intervention: Standard AO screw
Number of subjects: 7
Study 6390198 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus cyclophosphamide or azathioprine
Number of subjects: 100
Study 6390198 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 100
Study 6390198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide or azathioprine
Number of subjects: 100
Study 30765288 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE intervention (4-week video-delivered relaxation program)
Number of subjects: 40
Study 30765288 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 40
Study 30200928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based life-skills training program
Number of subjects: 1312
Study 30200928 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group
Number of subjects: 1312
Study 26739396 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 30
Study 26739396 — intervention group
Group type: COMPARATOR
Intervention: Sham RIPC (controls)
Number of subjects: 30
Study 26739396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RIPC and controls)
Number of subjects: 30
Study 26739396 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions
Number of subjects: 30
Study 27661466 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 234
Study 27661466 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Number of subjects: 234
Study 27661466 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 234
Study 27661466 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study 23448581 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive multifactorial intervention (PMI) strategy based on single‐pill amlodipine/atorvastatin (SPAA)
Number of subjects: 1417
Study 23448581 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) based on investigators' best clinical judgment
Number of subjects: 1417
Study 21063747 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of Fear of Isolation (FOI)
Number of subjects: 0
Study 21063747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Isolation (FOI) manipulation
Number of subjects: 0
Study 21063747 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IT and US participants
Number of subjects: 0
Study 20146867 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.5 microg/kg per min
Number of subjects: 20
Study 20146867 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 20
Study 17311572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 39
Study 17311572 — intervention group
Group type: COMPARATOR
Intervention: Specular Microscopy (SM)
Number of subjects: 39
Study 15159722 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day) added to ACEI
Number of subjects: 69
Study 15159722 — intervention group
Group type: COMPARATOR
Intervention: ACEI only (Control)
Number of subjects: 69
Study 11681653 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler (200 microg/dose of beclomethasone dipropionate)
Number of subjects: 10
Study 11681653 — intervention group
Group type: COMPARATOR
Intervention: pMDI plus Volumatic spacer (250 microg/dose of beclomethasone dipropionate)
Number of subjects: 10
Study 9773796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean urea reduction ratio (URR) among treatment centers, 64.9%
Number of subjects: 5817
Study 9773796 — intervention group
Group type: COMPARATOR
Intervention: Free-standing status of treatment centers
Number of subjects: 5817
Study 9773796 — intervention group
Group type: COMPARATOR
Intervention: Decreasing frequency of reported physician supervision of care
Number of subjects: 5817
Study 7797702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild exercise (range-of-motion)
Number of subjects: 0
Study 7797702 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild exercise programmes
Number of subjects: 0
Study 1972207 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 40
Study 1972207 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 40
Study 396647 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron tablets (Neo‐Fer) containing 0.20 g ferrous fumarate (60 mg Fe++)
Number of subjects: 19
Study 396647 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 19
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin gestations
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone level on the day of human chorionic gonadotrophin trigger
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of gonadotrophin
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin gestations (frozen embryo transfer subgroup)
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) (frozen embryo transfer subgroup)
Number of subjects: 2965
Study 31680064 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose of gonadotrophin (frozen embryo transfer subgroup)
Number of subjects: 2965
Study 27813466 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diversion
Number of subjects: 112